Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study

被引：1
|
作者：
Simonelli, M. [1 ]
Lorusso, D. [2 ]
Homicsko, K. [3 ,4 ]
Seguy, F. [5 ]
Kinder, M. [6 ]
Liu, Q. [7 ]
Croft, E. [8 ]
Kitano, S. [9 ]
机构：
[1] IRCCS Humanitas Res Hosp, Med Oncol, Rozzano, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS Rome & H, Gynaecol Oncol Unit, Milan, Italy
[3] UNIL, Ludiwg Inst Canc Res, Oncol Dept, Lausanne, Switzerland
[4] CHU Vaudois, Lausanne, Switzerland
[5] Incyte Biosci Int Sarl, Clin Dev, Morges, Switzerland
[6] Incyte Corp, Translat Sci, Wilmington, DE USA
[7] Incyte Corp, Biostats, Wilmington, DE USA
[8] Incyte Corp, Early Clin Dev, Wilmington, DE USA
[9] Canc Inst Hosp JFCR, Dept Adv Med Dev, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.684
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617MO
引用
收藏
页码：S495 / S495
页数：1
相关论文
共 50 条
  • [1] Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers
    Wee, S.
    Ye, M.
    Lo, Y.
    Hansbury, M.
    Shin, N.
    Weber, M.
    Roman, V.
    Huo, L.
    Skaggs, H.
    Drake, K.
    Kapilashrami, K.
    Stump, K.
    Yang, J.
    Chand, S.
    Timmers, C.
    Hummel, J.
    Ye, Y.
    Zhang, G.
    Yang, Y. O.
    Covington, M.
    Wu, L.
    Koblish, H.
    Kim, S.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S79 - S79
  • [2] Development of a CDK2-selective small molecule inhibitor INCB123667 for the treatment of CCNE1hi breast cancers
    Chand, Saswati
    Hansbury, Michael
    Lo, Yvonne
    Feldman, Pat
    Carl, Justine
    Timmers, Cynthia
    Hummel, Joshua
    Wee, Susan
    Kim, Sunkyu
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Phase I tolerability/safety of sunitinib in combination with capecitabine in patients (pts) with advanced solid tumors
    Verschraegen, C.
    Sweeney, C.
    Chiorean, G.
    Lee, F. C.
    Jones, S.
    Tye, L.
    Bello, A.
    Chao, R.
    Burris, H., III
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 111
  • [4] A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.
    Villalona-Calero, Miguel Angel
    Oh, Do-Youn
    Garralda, Elena
    Vieito, Maria
    Huang, Julius
    Piha-Paul, Sarina A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase I study of an oral isotype-selective histone deacetylase (HDAC) inhibitor in patients (pts) with advanced solid tumors
    Siu, L. L.
    Carducci, M.
    Chen, E. X.
    Maclean, M.
    Pili, R.
    King, S.
    Patterson, T.
    Li, Z.
    Kalita, A.
    Reid, G. K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 94 - 95
  • [6] A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
    Schwartz, G. K.
    Robertson, S.
    Shen, A.
    Wang, E.
    Pace, L.
    Dials, H.
    Mendelson, D.
    Shannon, P.
    Gordon, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase 1/2 study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors.
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
    Patel, Manish R.
    Juric, Dejan
    Henick, Brian S.
    Duska, Linda R.
    Wu, Rentian
    Guo, Jian
    Zhang, Hui
    Newberry, Kate
    Rinne, Mikael
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
    Wang, Y.
    Sheng, Q.
    Ji, T.
    Liang, J.
    Schomer, N.
    Fu, J.
    Zhang, T.
    Xiong, W.
    Cheng, D.
    Liu, Z.
    Ding, Q.
    Li, F.
    Chen, Y.
    Berk, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S494 - S494
  • [10] A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
    Yap, T. A.
    Moore, K. N.
    Patel, M.
    Henick, B. S.
    Do, D.
    Iheanacho, A.
    Zhang, H.
    Roche, M.
    Newberry, K.
    Hsieh, A.
    Juric, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S765 - S765
12345